Video

Ovarian Cancer Developments in 2017

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

The year 2017 has been an important one for the ovarian cancer field. New drugs have been approved that give hope to people who have tried other therapies but whose cancer has come back.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on the exciting developments in his field. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes patients will benefit greatly from these drugs.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.